TECVAYLI™ is a prescription medicine to treat adults with multiple myeloma who have already received at least 4 treatment regimens, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody to treat their multiple myeloma, and their cancer has come back or did not respond to prior treatment.

Sign Up for Updates

A new treatment option for adults with relapsed or refractory multiple myeloma who have received at least four treatment regimens.

Sign up now to stay informed about the latest updates on TECVAYLI™. Ask your doctor if TECVAYLI™ may be right for you.

file icon

Read about the FDA approval of TECVAYLI™.

See the Press Release

Download this brochure to review the Medication Guide and additional information about getting started with TECVAYLI™.

Get the Guide
chat support

Talk to your doctor about how to access patient support and resources for TECVAYLI™.

You can also call Janssen Compass™ at 844-NAV-1234 (844-628-1234)
to learn more about patient support for TECVAYLI™.

Sign up for the latest information about TECVAYLI

Janssen Biotech, Inc., our affiliates, and our service providers will use the information that you provide to send you personalized communications about TECVAYLI and relapsed or refractory multiple myeloma and your optional requests, and to research, develop, and improve our products and services. Please note that the subject line of email messages that you receive may include TECVAYLI or relapsed or refractory multiple myeloma. You may unsubscribe from these communications by following the instructions in them. Our Privacy Policy further governs the use of the information you provide.

This field is required.


First Name is required.
Last Name is required.
Valid Email is required.
Valid ZIP Code is required.

I am a...

Select your communication preference: